AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
Anglo-Swedish pharmaceutical major AstraZeneca reported a strong set of fourth-quarter and full-year 2005 results, which were broadly in line with analysts' expectations. The announcement was the first made under the leadership of new chief executive David Brennan.
The company saw an 8% increase in fourth-quarter sales to $6.29 billion (9% higher at constant exchange rates) and a 30% hike in pretax profits, which reached $1.69 billion, or $0.77 per share. For the full year, the firm achieved revenues of $23.95 billion, an increase of 12% on the 2004 figure, and 38% growth in pretax earnings to $6.67 billion, or $2.91 a share, a hike of 44% on the year-earlier period.
Leading products drive performance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze